Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.

Leukemia research - 1 Oct 2024

Travaglini Serena, Silvestrini Giorgia, Attardi Enrico, Fanciulli Maurizio, Scalera Stefano, Antonelli Silvia, Maurillo Luca, Palmieri Raffaele, Divona Mariadomenica, Ciuffreda Ludovica, Savi Arianna, Paterno Giovangiacinto, Ottone Tiziana, Barbieri Caterina, Maciejewski Jaroslaw P, Gurnari Carmelo, Ciliberto Gennaro, Voso Maria Teresa

Abstract excerpt

Acute myeloid leukemia (AML) with inv(16) is typically associated with a favourable prognosis. However, up to 40 % of patients will eventually experience disease relapse. Herein, we dissected the genomic and transcriptomic profile of inv(16) AML to identify potential prognostic markers and therapeutic vulnerabilities. Sequencing data from 222 diagnostic samples, including 44 relapse/refractory patients, revealed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Chromosome Inversion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 16

Share to Gene Expression Regulation, Leukemic

Share to Leukemia, Myeloid, Acute

Share to Oxidative Phosphorylation

Share to Recurrence

Share to Sulfonamides

Source

Identifiers

PMID: 39180902
DOI: 10.1016/j.leukres.2024.107568

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.PMID 39180902Read ↗

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read ↗

Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia.Semantic proximity Read ↗

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaSemantic proximity Read ↗

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaSemantic proximity Read ↗

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Multi-omics analysis of longitudinal patient samples reveals the molecular mechanism of AML progressionSemantic proximity Read ↗

OXPHOS mediators in acute myeloid leukemia patients: Prognostic biomarkers and therapeutic targets for personalized medicine.Semantic proximity Read ↗

Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signallingSemantic proximity Read ↗

A transcriptomic based deconvolution framework for assessing differentiation stages and drug responses of AMLSemantic proximity Read ↗

Next Generation Sequencing Study of clonal Evolution in AML Shows Mutations in RAS-MAPK Signaling Pathway as an Emergent Mechanism of Progression in Low-Intensity TreatmentsSemantic proximity Read ↗

Mitochondrial determinants of response and resistance to venetoclax <i>plus</i> cytarabine duplet therapy in acute myeloid leukemiaSemantic proximity Read ↗

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.